Advances in diagnosing mild cognitive impairment and Alzheimer's disease using 11C-PIB- PET/CT and common neuropsychological tests

Qing Zhao; Xinxin Du; Wenhong Chen; Ting Zhang; Zhuo Xu

doi:10.3389/fnins.2023.1216215

Advances in diagnosing mild cognitive impairment and Alzheimer's disease using ¹¹C-PIB- PET/CT and common neuropsychological tests

Front Neurosci. 2023 Jul 10:17:1216215. doi: 10.3389/fnins.2023.1216215. eCollection 2023.

Authors

Qing Zhao¹, Xinxin Du¹, Wenhong Chen², Ting Zhang^{3

4}, Zhuo Xu³

Affiliations

¹ Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
² Department of Sleep Medicine, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China.
³ Department of Rehabilitation, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
⁴ Rehabilitation Therapeutics, School of Nursing of Jilin University, Changchun, Jilin, China.

Abstract

Alzheimer's disease (AD) is a critical health issue worldwide that has a negative impact on patients' quality of life, as well as on caregivers, society, and the environment. Positron emission tomography (PET)/computed tomography (CT) and neuropsychological scales can be used to identify AD and mild cognitive impairment (MCI) early, provide a differential diagnosis, and offer early therapies to impede the course of the illness. However, there are few reports of large-scale ¹¹C-PIB-PET/CT investigations that focus on the pathology of AD and MCI. Therefore, further research is needed to determine how neuropsychological test scales and PET/CT measurements of disease progression interact.

Keywords: Alzheimer’s disease; PET/CT; amyloid; mild cognitive impairment; neuropsychological test scale.

Publication types

Review